Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin Duncan

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Journal of Neurology, Neurosurgery, and Psychiatry|August 31, 2012
KOMET: an unblinded, randomised, two parallel-group, stratified trial comparing the effectiveness of levetiracetam with controlled-release carbamazepine and extended-release sodium valproate as monotherapy in patients with newly diagnosed epilepsyEugen Trinka, Anthony G Marson, Wim Van Paesschen, et al.
American Journal of Respiratory and Critical Care Medicine|November 25, 2003
Sitaxsentan therapy for pulmonary arterial hypertensionRobyn J Barst, David Langleben, Adaani Frost, et al.
Journal of Crohn'S & Colitis|July 24, 2025
Efficacy and Safety of Upadacitinib Maintenance Therapy in Patients with Moderately to Severely Active Crohn's Disease: 2-Year Results from the U-ENDURE Long-Term Extension StudyEdward V Loftus, Geert D'Haens, Edouard Louis, et al.
Journal of Crohn'S & Colitis|November 20, 2025
Benefit-Risk Profile of Upadacitinib: Exploratory Post Hoc Analysis of Phase 2b/3 Studies in Patients With Moderately to Severely Active Ulcerative Colitis or Crohn's DiseaseSeverine Vermeire, Jean-Frederic Colombel, Silvio Danese, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 28, 2026
Long-term Safety of Upadacitinib in Patients with Inflammatory Bowel Disease: Integrated Analysis of Phase 2/3 StudiesRemo Panaccione, Julián Panés, Laurent Peyrin-Biroulet, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Journal of Neurology, Neurosurgery, and Psychiatry|August 31, 2012
KOMET: an unblinded, randomised, two parallel-group, stratified trial comparing the effectiveness of levetiracetam with controlled-release carbamazepine and extended-release sodium valproate as monotherapy in patients with newly diagnosed epilepsyEugen Trinka, Anthony G Marson, Wim Van Paesschen, et al.
American Journal of Respiratory and Critical Care Medicine|November 25, 2003
Sitaxsentan therapy for pulmonary arterial hypertensionRobyn J Barst, David Langleben, Adaani Frost, et al.
Journal of Crohn'S & Colitis|July 24, 2025
Efficacy and Safety of Upadacitinib Maintenance Therapy in Patients with Moderately to Severely Active Crohn's Disease: 2-Year Results from the U-ENDURE Long-Term Extension StudyEdward V Loftus, Geert D'Haens, Edouard Louis, et al.
Journal of Crohn'S & Colitis|November 20, 2025
Benefit-Risk Profile of Upadacitinib: Exploratory Post Hoc Analysis of Phase 2b/3 Studies in Patients With Moderately to Severely Active Ulcerative Colitis or Crohn's DiseaseSeverine Vermeire, Jean-Frederic Colombel, Silvio Danese, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 28, 2026
Long-term Safety of Upadacitinib in Patients with Inflammatory Bowel Disease: Integrated Analysis of Phase 2/3 StudiesRemo Panaccione, Julián Panés, Laurent Peyrin-Biroulet, et al.
Pageof 2